Latest:
Dr Bazhenova on Updated Data From the TRUST-I Trial of Taletrectinib in ROS1+ NSCLC
Lyudmila A. Bazhenova, MD, discusses updated efficacy data from the TRUST-I study of taletrectinib in ROS1-positive advanced non–small cell lung cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Lyudmila A. Bazhenova, MD, University of California San Diego
Latest:
Current and Future Use of MET Inhibitors in NSCLC
Healthcare professionals who manage patients with non–small cell lung cancer comment on their current experience using MET inhibitors as treatment for patients who harbor MET exon 14 skipping mutations and highlight strategies under investigation that will hopefully address current gaps in therapy.
M. Rachel McDowell, ANCP-BC
Latest:
Developing Best Practices to Mitigate Opioid Abuse Is a Priority in Cancer Care
Opioids are prescribed to manage cancer pain because the benefits generally outweigh the risks and because of the ethical imperative for quick relief. However, patients are exposed to a degree of risk for misuse and abuse.
M. Sue O'Dorisio, MD, PhD
Latest:
SPORE Grant Fuels New Research Projects on Neuroendocrine Tumors
With the FDA emphasis on personalized medicine for patients with orphan diseases, the National Cancer Institute has recently awarded a Neuroendocrine Tumor Specialized Program of Research Excellence to the Holden Comprehensive Cancer Center at the University of Iowa to fund both basic and clinical research on neuroendocrine tumors.
Madelaine Kuiper, MSN, RN
Latest:
Management and Treatment of Interstitial Lung Disease in Breast Cancer
Madelaine Kuiper, MSN, RN, discusses the adverse event of interstitial lung disease, which can occur in patients with HER2-positive metastatic breast cancer who have received fam-trastuzumab deruxtecan-nxki.
Madeleine Duvic, MD
Latest:
Dr. Duvic on Importance of Classifying T-Cell Lymphomas
Madeleine Duvic, MD, professor of Medicine and Dermatology, Blanche Bender Professorship in Cancer Research, director of the Research Fellowship Program, Department of Dermatology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, discusses the importance of classifying T-cell lymphomas and new targets in development. Duvic shared this insight during the 2016 OncLive State of the Science Summit on Hematologic Malignancies.
Madelyn Hanson, PhD
Latest:
Value and Market Access Considerations Often Missing From Trial Design
Having an evidence package at launch that
satisfies payers’ value criteria will increase the likelihood that payers will
reimburse the drug at a desirable price and enable patient access to innovative
treatments.
Madhav Dhodapkar, MBBS
Latest:
Dr Dhodapkar on the Role of Linvoseltamab in Relapsed/Refractory Multiple Myeloma
Madhav V. Dhodapkar, MBBS, discusses the advantages and disadvantages of bispecific antibodies and CAR T-cell therapy in patients with relapsed/refractory multiple myeloma, as well as the potential role for the bispecific antibody linvoseltamab in this treatment paradigm.
Maha H. Hussain, MB ChB
Latest:
Hussain and Taplin Talk Gender-Specific Struggles, Career Lessons in GU Oncology
Maha H.A. Hussain, MD, and Mary-Ellen Taplin, MD, sit down with OncLive® to travel the road that led them to specialize in genitourinary oncology, the challenges they experienced as a female in the field, and advice they would give to not only other rising female oncologists, but to their younger selves knowing what they know now.